{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:36:32Z","timestamp":1761561392883},"reference-count":28,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T00:00:00Z","timestamp":1260835200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc electrophysiol"],"published-print":{"date-parts":[[2010,5]]},"abstract":"<jats:p> <jats:bold>Anticoagulation in CHADS<jats:sub>2<\/jats:sub> Score 1<\/jats:bold>.\u2002<jats:bold><jats:italic>Background:<\/jats:italic><\/jats:bold> The revised ACC\/AHA\/ESC 2006 guideline recommends either aspirin or warfarin for the prevention of ischemic stroke in patients with atrial fibrillation (AF) in CHADS<jats:sub>2<\/jats:sub> score 1. We hypothesized that warfarin is superior to aspirin therapy for the prevention of stroke without increasing bleeding complication in AF patients with CHADS<jats:sub>2<\/jats:sub> score 1.<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Methods and Results:<\/jats:italic>\n          <\/jats:bold> Among 1,502 patients (mean 62.4 \u00b1 13.8 years old, male 65.4%) who were treated for nonvalvular AF without previous stroke, the number of patients with CHADS<jats:sub>2<\/jats:sub> score 1 was 422 (62.9 \u00b1 10.7 years old, male 290 [68.7%]) and their antithrombotic therapies were as follows: warfarin (n = 143), aspirin (n = 124), other antiplatelet (n = 45), and no antithrombosis (none: n = 110). We reviewed the incidences of ischemic stroke, mortality, and bleeding complications during the follow\u2010up period. Results were: (1) during 22.3 \u00b1 17.8 months of follow\u2010up, the incidence of ischemic stroke was significantly lower in warfarin (6 patients, 4.2%, mean international normalized ratio [INR] 2.0 \u00b1 0.5 IU) than in aspirin (16 patients, 12.9%, P = 0.008) than none (23 patients, 20.9%, P &lt; 0.001) without differences in all\u2010cause mortality. (2) The incidence of major bleeding (decrease in hemoglobin \u22652 g\/dL, requiring hospitalization or red blood cell transfusion \u22652 pints) was not different between warfarin (2.1%) and aspirin (0.8%, P = NS), but minor bleeding was more common in warfarin (10.5%) than in aspirin (2.4%, P = 0.007).<\/jats:p><jats:p> <jats:bold>\n            <jats:italic>Conclusion:<\/jats:italic>\n          <\/jats:bold> In AF patients with CHADS<jats:sub>2<\/jats:sub> score 1, warfarin was better to prevent ischemic stroke than aspirin without increasing the incidence of major bleeding complications. However, the incidence of minor bleeding was higher in the warfarin group than the aspirin group. <jats:italic>(J Cardiovasc Electrophysiol, Vol. 21, pp. 501\u2010507, May 2010)<\/jats:italic><\/jats:p>","DOI":"10.1111\/j.1540-8167.2009.01661.x","type":"journal-article","created":{"date-parts":[[2009,12,15]],"date-time":"2009-12-15T18:32:44Z","timestamp":1260901964000},"page":"501-507","source":"Crossref","is-referenced-by-count":34,"title":["The Effect and Safety of the Antithrombotic Therapies in Patients with Atrial Fibrillation and CHADS<sub>2<\/sub> Score 1"],"prefix":"10.1111","volume":"21","author":[{"given":"BYUNG HO","family":"LEE","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAE SEOK","family":"PARK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAE HYUNG","family":"PARK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JONG SEUNG","family":"PARK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JAE JIN","family":"KWAK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"EUI SEOCK","family":"HWANG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SOOK KYOUNG","family":"KIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"DONG HOON","family":"CHOI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"YOUNG\u2010HOON","family":"KIM","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HUI\u2010NAM","family":"PAK","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,4,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.18.2370"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.22.8.983"},{"issue":"2","key":"e_1_2_7_4_2","first-page":"CD001927","article-title":"Oral anticoagulants for preventing stroke in patients with non\u2010valvular atrial fibrillation and no previous history of stroke or transient ischemic attacks","author":"Aguilar MI","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.177292"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.22.2864"},{"issue":"6","key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence\u2010Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Singer DE","year":"2008","journal-title":"Chest"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1161\/circ.106.25.3143"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651587"},{"key":"e_1_2_7_10_2","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00415-007-0646-0","article-title":"Measuring disability in stroke: Relationship between the modified Rankin scale and the Barthel index","volume":"254","author":"Uyttenboogaart M","year":"2007","journal-title":"J Neurol"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.STR.0000258355.23810.c6"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199011293232201"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022913"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1161\/01.CIR.0000121736.16643.11","article-title":"Relationships between sinus rhythm, treatment, and survival in the atrial fibrillation follow\u2010up investigation of rhythm management (AFFIRM) study","volume":"109","author":"The AFFIRM Investigators","year":"2004","journal-title":"Circulation"},{"key":"e_1_2_7_15_2","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1161\/STROKEAHA.107.500199","article-title":"Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE\u2010W)","volume":"39","author":"Healey JS","year":"2008","journal-title":"Stroke."},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61233-1"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afl129"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.19.2441"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01672.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0341"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01672.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.22.2612"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000022665.18619.83"},{"key":"e_1_2_7_24_2","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1016\/j.ehj.2003.08.014","article-title":"Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long\u2010standing persistent atrial fibrillation. Results of a prospective and controlled study","volume":"24","author":"Ueng KC","year":"2003","journal-title":"Eur Heart J"},{"key":"e_1_2_7_25_2","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1093\/eurheartj\/ehl135","article-title":"Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation","volume":"27","author":"Yin Y","year":"2006","journal-title":"Eur Heart J"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.09.063"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.730101"},{"key":"e_1_2_7_28_2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2006.08.086","article-title":"Candesartan in the prevention of relapsing atrial fibrillation","volume":"120","author":"Tveit A","year":"2007","journal-title":"Int J Cardiol."},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805710"}],"container-title":["Journal of Cardiovascular Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1540-8167.2009.01661.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1540-8167.2009.01661.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T23:07:48Z","timestamp":1697324868000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1540-8167.2009.01661.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4,15]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1111\/j.1540-8167.2009.01661.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1540-8167.2009.01661.x","archive":["Portico"],"relation":{},"ISSN":["1045-3873","1540-8167"],"issn-type":[{"value":"1045-3873","type":"print"},{"value":"1540-8167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4,15]]}}}